MedTrace Logo

Spirulina Supplementation and Cardiovascular Risk in Obese Caucasians With Treated Hypertension

NCT02575690 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-05-05

No results posted yet for this study

Summary

Potential protective cardiovascular effect of Spirulina maxima supplementation was studied in a double-blind placebo-controlled trial of obese subjects with treated hypertension, each randomized to receive spirulina or a placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

Spirulina

Individuals receive 2 g of spirulina daily, for 3 months.

OTHER

Placebo

Individuals receive a placebo daily, for 3 months.

Sponsors & Collaborators

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Pawel Bogdanski, MD, PhD · Poznan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-05-31
Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02575690 on ClinicalTrials.gov